FDA gets meager funding boost

Any big fix at the FDA may have to wait for a new president. The White House's proposed budget includes a funding increase of just 5.7 percent for the agency, a hike that's significantly absorbed by inflation. It's a far cry from the double-or-nothing some experts have said is crucial to bringing the FDA up to speed.

The $2.4 billion budget won't be greeted by cheers from any but the most die-hard anti-government types. Over the past couple of months, report after report has shown that FDA is in dire need of more bucks and more bodies to deal with big leaps forward in science and huge increases in imports of food and drugs.

Of course Congress might boost FDA funding levels, but that boost would have to make it past the president's desk. For his part, Commissioner Andrew von Eschenbach sounded sanguine about the proposal--"This budget enables us to  continue development of the staff and programs necessary," he said in a statement--but it is his boss's budget, after all. Other observers weren't so satisfied. Without Congressional intervention, the agency will be stuck "treading water," one expert said.

- see the FDA's release
- read the report from USA Today
- check out the article in the Wall Street Journal

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.